The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The study, published in Nucleic Acids Research, introduces BLU-VIPR, a method that allows researchers to control the gene-editing tool CRISPR using ... which then binds to Cas9, leading to the ...

Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CRISPR Therapeutics insiders own about US$17m worth of ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

CRISPR-Cas9 gene editing technology has emerged as one of the most transformative advancements in medicine and biotechnology. This precise tool allows scientists to make targeted modifications to ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

In a recent study published in Science Advances, researchers reported using synthetic genomics and a clustered regularly interspaced short palindromic repeats-­associated protein 9 (CRISPR-Cas9 ...

The landscape of drug discovery is evolving rapidly, driven by breakthroughs in AI, high-throughput screening and precision medicine. As researchers work to develop safer, more effective therapies, ...

Berkeley—Nobel Laureate Jennifer Doudna, PhD, professor of biochemistry, biophysics, and structural biology at UC Berkeley, aspires for “CRISPR to become the standard of medical care for ...